Aurobindo Pharma Limited

NSEI:AUROPHARMA Lagerbericht

Marktkapitalisierung: ₹717.5b

Aurobindo Pharma Management

Management Kriterienprüfungen 3/4

Aurobindo Pharma CEO ist Kambam Reddy , ernannt in Jun 2006, hat eine Amtszeit von 18.42 Jahren. Die jährliche Gesamtvergütung beträgt ₹45.05M , bestehend aus 50.9% Gehalt und 49.1% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 5.61% der Aktien des Unternehmens, im Wert von ₹40.28B . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 9.5 Jahre bzw. 5.5 Jahre.

Wichtige Informationen

Kambam Reddy

Geschäftsführender

₹45.0m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts50.9%
Amtszeit als Geschäftsführer18.4yrs
Eigentum des Geschäftsführers5.6%
Durchschnittliche Amtszeit des Managements9.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder5.5yrs

Jüngste Management Updates

This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Aug 23
This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Recent updates

Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Nov 12
Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price

Oct 20
Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price

Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Sep 10
Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Aug 23
This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Aug 13
Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Jun 20
Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

May 29
Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

May 22
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Apr 10
Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Jan 14
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Dec 27
Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Sep 07
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Jun 14
Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?

May 21
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price

Feb 11
Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price

Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly

Jan 09
Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly

Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?

Nov 02
Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?

We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt

Jun 20
We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Kambam Reddy im Vergleich zu den Einnahmen von Aurobindo Pharma verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

₹36b

Jun 30 2024n/an/a

₹35b

Mar 31 2024₹45m₹23m

₹32b

Dec 31 2023n/an/a

₹28b

Sep 30 2023n/an/a

₹23b

Jun 30 2023n/an/a

₹20b

Mar 31 2023₹37m₹19m

₹19b

Dec 31 2022n/an/a

₹20b

Sep 30 2022n/an/a

₹21b

Jun 30 2022n/an/a

₹24b

Mar 31 2022₹27m₹14m

₹26b

Dec 31 2021n/an/a

₹29b

Sep 30 2021n/an/a

₹52b

Jun 30 2021n/an/a

₹53b

Mar 31 2021₹23m₹20m

₹53b

Dec 31 2020n/an/a

₹54b

Sep 30 2020n/an/a

₹31b

Jun 30 2020n/an/a

₹30b

Mar 31 2020₹15m₹13m

₹28b

Dec 31 2019n/an/a

₹26b

Sep 30 2019n/an/a

₹26b

Jun 30 2019n/an/a

₹25b

Mar 31 2019₹15m₹13m

₹24b

Dec 31 2018n/an/a

₹23b

Sep 30 2018n/an/a

₹22b

Jun 30 2018n/an/a

₹24b

Mar 31 2018₹15m₹13m

₹24b

Vergütung im Vergleich zum Markt: KambamDie Gesamtvergütung ($USD533.60K) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Indian ($USD776.13K).

Entschädigung vs. Einkommen: KambamDie Bezüge der Mitarbeiter sind im vergangenen Jahr um mehr als 20 % gestiegen.

Geschäftsführer

Kambam Reddy (66 yo)

18.4yrs

Amtszeit

₹45,048,542

Vergütung

Mr. Kambam Nithyananda Reddy has been Vice Chairman of Aurobindo Pharma Limited since June 1, 2012 and serves as a Whole Time Director of Aurobindo Pharma Limited since December 26, 1986 and serves as Mana...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Kambam Reddy
Vice Chairman & MD18.4yrs₹45.05m5.61%
₹ 40.3b
Mettu Madan Reddy
Whole-Time Directorno data₹60.15mkeine Daten
Makkapati Satakarni
President of Biologics8.8yrs₹300.00kkeine Daten
Santhanam Subramanian
Chief Financial Officer10.3yrs₹21.06mkeine Daten
S. Kumar
President of Technicalno datakeine Datenkeine Daten
B. Reddy
Compliance Officer & Company Secretary8.4yrs₹4.76mkeine Daten
G. Prasad
Senior Vice President of Global Finance & Operationsno datakeine Datenkeine Daten
Sudhir Singhi
Head of Global Finance Operationsno datakeine Datenkeine Daten
A. Rama Rao
Chief Quality Officer -Corporate QAno datakeine Daten0.025%
₹ 176.7m
V. Handa
President of Chemical Researchno datakeine Datenkeine Daten
Gita Rao
President of RAD-IIno data₹9.14mkeine Daten
Hemant Sharma
President-ARDno data₹10.09mkeine Daten

9.5yrs

Durchschnittliche Betriebszugehörigkeit

60yo

Durchschnittliches Alter

Erfahrenes Management: AUROPHARMADas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (9.5 ).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Kambam Reddy
Vice Chairman & MD37.9yrs₹45.05m5.61%
₹ 40.3b
Mettu Madan Reddy
Whole-Time Director18.2yrs₹60.15mkeine Daten
Makkapati Satakarni
President of Biologicsless than a year₹300.00kkeine Daten
Penaka Venkata Reddy
Non-Executive Director37.9yrs₹600.00k3.07%
₹ 22.0b
Penaka Sarath Reddy
Non-Executive Director17.2yrs₹900.00kkeine Daten
Santanu Mukherjee
Independent Director1.8yrs₹2.50mkeine Daten
Deepali Pant Joshi
Independent Directorno data₹500.00kkeine Daten
Savitha Mahajan
Additional Non-Executive Independent Director6.9yrs₹2.20mkeine Daten
Venkat Chalasani
Independent Director of Apitoria Pharma Private Limited1.6yrskeine Datenkeine Daten
Mangalam Kumar
Independent Non-Executive Chairmanless than a yearkeine Datenkeine Daten
Girish Vanvari
Non-Executive Independent Director4yrs₹2.60mkeine Daten

5.5yrs

Durchschnittliche Betriebszugehörigkeit

64yo

Durchschnittliches Alter

Erfahrener Vorstand: AUROPHARMADie Vorstandsmitglieder gelten als erfahren (5.5 Jahre durchschnittliche Amtszeit).